Anti-Ischemic Activity of Fabomotizole Hydrochloride under Conditions of Endothelial Dysfunction
- Authors: Tsorin I.B.1, Barchukov V.V.1, Vititnova M.B.1, Kryzhanovskii S.A.1, Seredenin S.B.1
- 
							Affiliations: 
							- V. V. Zakusov Research Institute of Pharmacology
 
- Issue: Vol 167, No 5 (2019)
- Pages: 634-636
- Section: Pharmacology and Toxicology
- URL: https://journals.rcsi.science/0007-4888/article/view/241976
- DOI: https://doi.org/10.1007/s10517-019-04586-x
- ID: 241976
Cite item
Abstract
Anti-ischemic activity of fabomotizole hydrochloride was studied on the model of subendocardial ischemia in rats with endothelial dysfunction. Endothelial dysfunction was modeled by intragastric administration of methionine (3 g/kg, once a day for 7 days). Acute subendocardial ischemia was induced in narcotized rats by intraperitoneal injection of isoproterenol (20 μg/kg/min over 5 min). Fabomotizole hydrochloride (intraperitoneally, 15 mg/kg) significantly reduced isoproterenol-induced ST segment depression in animals with endothelial dysfunction and with intact vasculature.
About the authors
I. B. Tsorin
V. V. Zakusov Research Institute of Pharmacology
														Email: SAK-538@yandex.ru
				                					                																			                												                	Russian Federation, 							Moscow						
V. V. Barchukov
V. V. Zakusov Research Institute of Pharmacology
														Email: SAK-538@yandex.ru
				                					                																			                												                	Russian Federation, 							Moscow						
M. B. Vititnova
V. V. Zakusov Research Institute of Pharmacology
														Email: SAK-538@yandex.ru
				                					                																			                												                	Russian Federation, 							Moscow						
S. A. Kryzhanovskii
V. V. Zakusov Research Institute of Pharmacology
							Author for correspondence.
							Email: SAK-538@yandex.ru
				                					                																			                												                	Russian Federation, 							Moscow						
S. B. Seredenin
V. V. Zakusov Research Institute of Pharmacology
														Email: SAK-538@yandex.ru
				                					                																			                												                	Russian Federation, 							Moscow						
Supplementary files
 
				
			 
					 
						 
						 
						 
						 
				 
  
  
  
  
  Email this article
			Email this article  Open Access
		                                Open Access Access granted
						Access granted Subscription Access
		                                		                                        Subscription Access
		                                					